Methodological Considerations for the Human Abuse Potential Evaluation of Emerging Drug Therapies with Psychedelic Properties

Key Biomarkers of Immunomodulation: Complement Factors and Cytokines

Quantitation of the COVID-19 Neutralizing Antibody Bamlanivimab* Using Mitra® Microsampling and Mass Spectrometry

Comparing Cytokine Data to In-Life Parameters on Nonhuman Primates in Nonclinical Toxicology Studies

Rapid Development of a Liquid-filled, Hard-Shell Capsule Formulation of Cannabidiol

The Advantages of Liquid-Filled Capsules Over Tablets in All Phases of Drug Development

.custom-column-left-text { float: left; width: 50%; padding-right: 10px; } .custom-column-right-text { float: right; width: 45%; text-align:center; } @media only screen and (max-width: 600px) { .custom-column-left-text, .custom-column-right-text, .custom-column-flc-ebook-text { float:none; width:80%; margin:0 auto; } }

As the incidence of mental health issues increases around the world, most recently exacerbated by the COVID-19 pandemic that has pushed depression to nearly triple the rate

.custom-column-left-text { float: left; width: 45%; padding-right: 10px; } .custom-column-right-text { float: right; width: 45%; text-align:center; } @media only screen and (max-width: 600px) { .custom-column-left-text, .custom-column-right-text, .custom-column-flc-ebook-text { float:none; width:80%; margin:0 auto; } }

Tying together the phases of your drug development program are the essential research support services that help your drug candidates not only meet their milestones, but also regulator

Parallelism Challenges When Using Commercial Kits for Biomarker Quantitation

Subscribe to